EyePoint Pharmaceuticals Inc (EYPT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
LABORATORY ANALYTICAL INSTRUMENTS
CEO:
Nancy S. Lurker
Employees:
120
480 PLEASANT STREET, SUITE B300, WATERTOWN, MA 02472
617-926-5000

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Data derived from most recent annual or quarterly report
Market Cap 215.152 Million Shares Outstanding34.984 Million Avg 30-day Volume 590.827 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue7.2042 Debt to Equity0.0 EBITDA-96.76 Million
Price to Book Value5.2259 Operating Margin-240.9331 Enterprise Value170.333 Million
Current Ratio2.35 EPS Growth-0.243 Quick Ratio2.136
1 Yr BETA 1.5481 52-week High/Low 15.63 / 2.19 Profit Margin-235.5149
Operating Cash Flow Growth117.9431 Free Cash Flow to Firm (FCFF) TTM 24.492 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score-5.6393

Are you looking for this stock instead?

View SEC Filings from EYPT instead.

View recent insider trading info

EyePoint Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EYPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EYPT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-10-17 by DUTY STUART
  • 3: filed on 2023-10-17 by DUTY STUART
  • 4: filed on 2023-10-17 by ELSTON GEORGE
  • 4: filed on 2023-09-06 by ESSEX WOODLANDS FUND IX-GP, L.P.
  • 4: filed on 2023-07-12 by DUKER JAY S.
  • 4: filed on 2023-07-12 by LURKER NANCY
  • 4: filed on 2023-07-12 by ZADEREJ KAREN L.
  • 4: filed on 2023-06-22 by LANDIS JOHN B.
  • 4: filed on 2023-06-22 by ZADEREJ KAREN L.
  • 4: filed on 2023-06-22 by PINE MICHAEL CRAIG

    • Events (8k)

  • 8-K: filed on 2023-11-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-26:
  • 144/A: filed on 2023-05-26:
  • 144/A: filed on 2023-05-26:
  • 144: filed on 2023-08-22:
  • 144: filed on 2023-08-22:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ELSTON GEORGE CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-10-16 5

    DUTY STUART

    • Director
    		 0 2023-10-16 2

    EW HEALTHCARE PARTNERS, L.P.

    EW HEALTHCARE PARTNERS-A, L.P.

    ESSEX WOODLANDS FUND IX-GP, L.P.

    ESSEX WOODLANDS IX, LLC

    • 10% Owner
    • SEE FOOTNOTES 1 AND 3SEE FOOTNOTES 1 AND 3
    		3,490,921 2023-09-01 7

    ZADEREJ KAREN L.

    • Director
    		 2,000 2023-07-11 2

    LURKER NANCY EXECUTIVE VICE CHAIR

    • Officer
    • Director
    		 0 2023-07-10 5

    DUKER JAY S. PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-07-10 4

    ADAMIS ANTHONY P

    • Director
    		 2,000 2023-06-23 2

    ANDO GORAN

    • Director
    		 0 2023-06-20 2

    DICICCO WENDY F

    • Director
    		 0 2023-06-20 2

    GUYER DAVID R

    • Director
    		 0 2023-06-20 2

    LANDIS JOHN B.

    • Director
    		 0 2023-06-20 2

    PAGGIARINO DARIO A. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-06-20 3

    JONES DAVID SCOTT SVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-06-20 3

    PINE MICHAEL CRAIG CHIEF CORP DEV.&STRAT. OFFICER

    • Officer
    		 0 2023-06-20 3

    LIU YE

    • Director
    		 3,010,721 2023-05-30 1

    GODSHALL DOUGLAS EVAN

    • Director
    		 19,016 2021-06-22 0

    OCUMENSION THERAPEUTICS

    • 10% Owner
    		 3,010,722 2020-12-31 0

    MAZZO DAVID J

    • Director
    		 252,583 2020-02-28 0

    PETERSON KRISTINE

    • Director
    		 59,167 2020-02-28 0

    ROSS LEONARD S SEE REMARKS

    • Officer
    		 96,711 2019-06-27 0

    ROGERS MICHAEL W

    • Director
    		 159,167 2019-06-25 0

    PRICE DAVID CFO

    • Officer
    		 300,000 2019-06-25 0

    BLUM LEONARD M SEE REMARKS

    • Officer
    		 0 2018-05-14 0

    BARRY JAMES J

    • Director
    		 No longer subject to file 2018-05-07 0

    EASTMAN RONALD W

    • Director
    • 10% Owner
    		 8,606,324 2018-03-28 0

    JORN DEBORA EVP, CORP. & COMM'L DEV.

    • Officer
    		 0 2017-06-27 0

    FREEDMAN LORI SEE REMARKS

    • Officer
    		 0 2016-07-21 0

    ASHTON PAUL PRESIDENT & CEO

    • Officer
    • Director
    		 467,522 2016-03-18 0

    SAVAS PETER G

    • Director
    		 0 2015-12-03 0

    HOPPER PAUL

    • Director
    		 0 2013-12-18 0

    SOJA MICHAEL VP FINANCE, CFO & TREASURER

    • Officer
    		 0 2008-09-10 0

    WOODTHORPE KATHERINE

    • Director
    		 0 2008-06-19 0

    PFIZER INC

    • 10% Owner
    		 74,483,748 2007-08-27 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ELSTON GEORGE - Officer CHIEF FINANCIAL OFFICER

    		2023-10-17 16:47:31 -0400 2023-10-16 A 30,000 a 30,000 direct

    DUTY STUART - Director

    		2023-10-17 16:49:33 -0400 2023-10-16 A 60,000 a 60,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 22:15:04 UTC 4.6579 0.6621 500000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 21:45:03 UTC 4.6579 0.6621 500000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 21:15:04 UTC 4.6579 0.6621 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 20:45:04 UTC 4.6579 0.6621 500000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 20:15:04 UTC 4.6658 0.6542 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 19:45:03 UTC 4.6658 0.6542 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 19:15:04 UTC 4.6658 0.6542 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 18:45:03 UTC 4.6658 0.6542 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 18:15:03 UTC 4.6658 0.6542 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 17:45:04 UTC 4.6681 0.6519 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 17:15:04 UTC 4.6681 0.6519 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 16:45:04 UTC 4.6681 0.6519 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 16:15:04 UTC 4.6681 0.6519 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 15:45:03 UTC 4.635 0.685 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 15:15:03 UTC 4.635 0.685 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 14:45:04 UTC 4.6324 0.6876 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 14:15:04 UTC 4.6324 0.6876 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 13:45:04 UTC 4.6591 0.6609 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 13:15:03 UTC 4.6591 0.6609 450000
    EYEPOINT PHARMACEUTICALS INC EYPT 2023-11-28 12:45:04 UTC 4.6591 0.6609 450000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Squarepoint Ops LLC EyePoint Pharmaceuticals Inc 0.5% 2019-10-16 GERMANY
    Squarepoint Ops LLC EyePoint Pharmaceuticals Inc 0.6% 2019-11-05 GERMANY

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments